OakChart

Eikon Therapeutics Inc

EIKNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.67+0.54 (8.81%)
2026-11-12 05:49 CET
Market cap
361.28 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-88.41 USD m
Free cash flow, TTM
-65.21 USD m
EPS diluted, TTM
-1.63
P/E
-
Compare

Price

EIKN against its 20 and 50-day averages
2050beatmiss
5.007.5010.0012.5015.001.6M3.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EIKNclose 6.6720-day 6.4850-day 7.736.6752w low

61.7% under the 52-week high of 17.40 on 5 Feb 2026. 52-week low 5.01 on 30 Oct 2026. Last 15 sessions, 65.5% high to low

Volume 0.76× normal · the line is the 50-bar volume average

Profile

EIKN
52-week range, 13% of the way up
5.0117.40

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

IndexRUT
IPOFeb 05, 2026
ATR, 14d0.66
Rel volume0.76
Short float21.93%
Insider own53.39%
Inst own42.66%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap361.28M
Enterprise Value81.92M
Income-
Sales-
Book/sh8.62
Cash/sh9.81
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOFeb 05, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.77
P/C0.68
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.89
Current Ratio9.89
Debt/Eq0.54
LT Debt/Eq0.52
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-7.28
EPS next Q-1.70
EPS this Y93.95%
EPS next Y-4.37%
EPS next 5Y63.64%
EPS past 3/5Y-13.35% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-10.51%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-2.84% -

Ownership

Insider Own53.39%
Insider Trans0.31%
Inst Own42.66%
Inst Trans2.99%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.89%
SMA50-13.75%
SMA200-34.91%
Trades-

Technical

Shs Outstand54.15M
Shs Float25.25M
Short Float21.93%
Short Ratio9.61
Short Interest5.54M
52W High17.40 -61.67%
52W Low5.01 33.13%
Volatility9.90% 11.36%
ATR (14)0.66
RSI (14)49.65
Beta-
Rel Volume0.76
Avg Volume576.14K
Volume440,008

Performance

Perf Week4.38%
Perf Month-0.74%
Perf Quarter-35.43%
Perf Half Y-45.82%
Perf YTD-60.88%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.57
Target Price24.33
Prev Close6.13
Price6.67
Change %8.81%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedHH.C. WainwrightBuy$23+244.8%
Mar 02, 2026InitiatedMMorgan StanleyOverweight$32+379.8%
Mar 02, 2026InitiatedMMizuhoOutperform$26+289.8%
Mar 02, 2026InitiatedJJP MorganOverweight$29+334.8%
Mar 02, 2026InitiatedCCantor FitzgeraldOverweight
Mar 02, 2026InitiatedBBofA SecuritiesBuy$34+409.7%
Feb 26, 2026InitiatedWWedbushUnderperform$7+4.9%

Peers

Mkt cap
TickerCompanyMkt cap
IDYAIdeaya Biosciences Inc3.16B
REPLReplimune Group Inc2.06B
TNGXTango Therapeutics Inc4.36B
IMCRImmunocore Holdings plc ADR1.63B
IOVAIovance Biotherapeutics Inc3.74B
AZNAstrazeneca plc287.66B
ORICORIC Pharmaceuticals Inc932.88M
ARVNArvinas Inc452.51M
RCUSArcus Biosciences Inc2.71B
MRKMerck & Co Inc362.83B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Column Group IV GP, LP10% OwnerSep 03 '26Buy11.5689,2001,031,04589,200Sep 08 04:33 PM
Column Group IV GP, LP10% OwnerFeb 06 '26Buy18.002,117,76038,119,6804,312,139Feb 09 09:19 PM
Foresite Capital Management IV10% OwnerFeb 04 '26Buy18.0055,555999,9901,318,983Feb 06 07:37 PM
FRAZIER KENNETH CDirectorFeb 04 '26Buy18.00111,1111,999,998111,111Feb 06 06:33 PM
Wolfe JoshDirectorFeb 04 '26Buy18.00277,7764,999,968138,888Feb 06 06:27 PM
Lux Venture Partners V, LLC10% OwnerFeb 04 '26Buy18.00277,7764,999,968138,888Feb 06 06:25 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
OMFSInvesco Russell 2000 Dynamic Multifactor ETFAUM: 263.85M

News

latest 14 of 50
  • Eikon Therapeutics to Participate in Multiple Investor Conferences in November (GlobeNewswire) +6.97%
  • Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress (GlobeNewswire) -23.69%
  • Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress (GlobeNewswire) -11.89%
  • Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress (GlobeNewswire)
  • Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer (GlobeNewswire) +7.56%
  • Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
  • Eikon Therapeutics to Participate in Investor Conferences in September 2026 (GlobeNewswire)
  • Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald (GlobeNewswire) +11.27%
  • Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +6.97%
  • Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma (GlobeNewswire) +5.14%
  • Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board (GlobeNewswire)
  • Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer (GlobeNewswire) +11.01%
  • Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress (GlobeNewswire)
  • Eikon Therapeutics to Join the Russell 3000 Index (GlobeNewswire) +16.24%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.630-1.585-1.6300.000.006
2026Q12026-05-11-2.461-1.978-1.5320.000.005
2025Q42026-03-30-27.000-3.560-1.4710.000.001
2026Q3---1.698--0.007
2026Q4---1.818--0.007
2027Q1---1.841--0.003
2027Q2---1.881--0.003
2027Q3---1.879--0.003
2027Q4---1.640--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-115.29-10.293-78.6270.000.00
2026FY--6.977--0.00
2027FY--7.282--0.00
2028FY--5.542--0.00
2029FY--5.961--25.19
2030FY--5.505--90.93

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-275000.000.000.00
2026Q3S2026-10-154000.000.000.00
2026Q3S2026-08-203000.000.000.00
2026Q3S2026-08-193000.000.000.00
2026Q3S2026-08-164000.000.000.00
2026Q3S2026-08-145000.000.000.00
2026Q3S2026-08-135000.000.000.00
2026Q3S2026-06-035000.000.000.00
2026Q3S2026-05-124000.000.000.00
2026Q3S2026-03-304000.000.000.00
2026Q3S2026-02-273000.000.000.00
2026Q3S2026-02-251000.000.000.00
2026Q3R2026-10-28710-1.70-1.79-1.50
2026Q3R2026-10-27722-1.70-1.79-1.50

Estimate history

EPS, annual-4.796-4.832-6.163
Period202320242025
EPS, quarterly-1.287-1.477-1.943-1.471-1.532-1.633
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Sales, annual000
Period202320242025
Sales, quarterly000000
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Shares, annual50.45550.45554.13954.149
Period202320242025MRQ
Shares, quarterly50.45550.45554.13954.13954.13954.149
PeriodQ4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A5.0324.1825.3917.75
Gross Profit-5.03-24.18-25.39-17.75
Selling, General and Administrative Excl. Other88.36314.77234.95247.99
Research and Development75.46250.32204.54207.26
Other Operating Expense0.000.000.000.00
Operating Income-93.39-338.94-260.34-265.74
Interest Expense-0.840.030.04
Unusual Expense0.000.000.000.00
Net Income Before Taxes-88.41-324.25-243.81-242.00
Income Taxes0.000.000.000.00
Consolidated Net Income-88.41-324.25-243.81-242.00
Net Income From Continuing Operations-88.41-324.25-243.81-242.00
Net Income-88.41-333.64-243.81-242.00
EPS (Recurring)-1.63-6.16-4.83-4.80
EPS (Basic, Before Extraordinaries)-1.63-6.16-4.83-4.80
EPS (Diluted)-1.63-6.16-4.83-4.80
EBITDA-88.36-314.77-234.95-247.99
Non-Operating Income (Expense)4.9915.5316.5623.78
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense4.2218.0412.439.54
Shares Outstanding54.1554.1450.4550.45
Market Capitalization361.28361.28--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A5.035.115.116.306.476.21
Gross Profit-5.03-5.11-5.11-6.30-6.47-6.21
Selling, General and Administrative Excl. Other88.3682.2278.06103.3464.9261.56
Research and Development75.4670.0565.2369.1956.5953.86
Other Operating Expense0.000.000.000.000.000.00
Operating Income-93.39-87.34-83.17-109.64-71.38-67.78
Interest Expense-----0.01
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-88.41-82.96-79.66-105.21-68.24-64.92
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-88.41-82.96-79.66-105.21-68.24-64.92
Net Income From Continuing Operations-88.41-82.96-79.66-105.21-68.24-64.92
Net Income-88.41-82.96-79.66-105.21-74.54-64.92
EPS (Recurring)-1.63-1.53-1.47-1.94-1.48-1.29
EPS (Basic, Before Extraordinaries)-1.63-1.53-1.47-1.94-1.48-1.29
EPS (Diluted)-1.63-1.53-1.47-1.94-1.48-1.29
EBITDA-88.36-82.22-78.06-103.34-64.92-61.56
Non-Operating Income (Expense)4.994.383.514.433.142.86
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense4.222.783.867.212.973.18
Shares Outstanding54.1554.1454.1454.1450.4550.45
Market Capitalization361.28572.38523.69---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments336.38220.51430.41
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets12.547.386.01
Total Current Assets348.92227.89436.43
Net Property, Plant & Equipment233.86259.1386.88
Total Investments and Advances7.771.301.30
Other Assets4.182.921.10
Total Assets594.73491.24525.71
Short Term Debt Incl. Current Port. of LT Debt10.039.315.05
Accounts Payable0.6817.582.19
Other Current Liabilities44.3029.5624.20
Total Current Liabilities55.0156.4531.44
Long Term Debt247.29193.1526.69
Provision for Risks Charges0.000.000.00
Other Liabilities10.005.350.73
Total Liabilities312.30254.9558.86
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value1,161.47808.22808.22
Common Equity-879.03-571.93-341.37
Total Shareholders Equity282.44236.29466.85
Accumulated Minority Interest0.000.000.00
Total Equity282.44236.29466.85
Total Liabilities & Stockholders Equity594.73491.24525.71
Book Value Per Share-16.24-11.34-6.77
Tangible Book Value Per Share-16.24-11.34-6.77
Price to Book Ratio0.77--
Return on Assets-59.72-47.95-
Return on Equity-125.02-69.35-
Return on Invested Capital-61.21-56.77-49.03
Quick Ratio6.344.0413.88
Current Ratio6.344.0413.88

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-88.41-324.25-243.81-242.00
Depreciation5.0624.1825.3917.75
Other Funds (Non Cash)3.8333.722.9723.43
Funds from Operations-79.52-266.35-215.45-200.82
Extraordinary Item0.000.000.000.00
Changes in Working Capital14.5677.8380.659.98
Cash from Operating Activities-64.96-188.52-134.80-190.85
Capital Expenditures-0.25-46.74-84.80-28.51
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments46.68-134.60236.15165.46
Purchase of Investments-79.82-444.10-360.35-804.74
Sale Or Maturity of Investments126.50309.50596.50970.20
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities46.43-181.34151.35136.95
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.00---
Change in Capital Stock0.03352.050.24105.81
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock0.03352.050.24105.81
Proceedsfrom Stock Options0.03352.050.24105.81
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities0.03352.050.24105.81
Net Change in Cash-18.50-17.8116.8051.91
Free Cash Flow-65.21-235.26-219.60-219.36
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Cash & Short Term Investments531.58512.58336.38--220.51
Short Term Receivables0.000.000.00--0.00
Inventories0.000.000.00--0.00
Other Current Assets15.4016.9212.54--7.38
Total Current Assets546.98529.50348.92--227.89
Net Property, Plant & Equipment224.21229.13233.86--259.13
Total Investments and Advances7.8491.647.77--1.30
Other Assets0.540.564.18--2.92
Total Assets779.57850.83594.73--491.24
Short Term Debt Incl. Current Port. of LT Debt9.459.7410.03--9.31
Accounts Payable6.566.000.68--17.58
Other Current Liabilities39.2929.3244.30--29.56
Total Current Liabilities55.3045.0655.01--56.45
Long Term Debt242.77245.09247.29--193.15
Provision for Risks Charges0.000.000.00--0.00
Other Liabilities15.0010.0010.00--5.35
Total Liabilities313.07300.15312.30--254.95
Non-Equity Reserves0.000.000.00--0.00
Preferred Stock - Carrying Value0.000.001,161.47--808.22
Common Equity466.50550.67-879.03---571.93
Total Shareholders Equity466.50550.67282.44--236.29
Accumulated Minority Interest0.000.000.00--0.00
Total Equity466.50550.67282.44--236.29
Total Liabilities & Stockholders Equity779.57850.83594.73--491.24
Book Value Per Share8.6210.17-16.24---11.34
Tangible Book Value Per Share8.6210.17-16.24---11.34
Price to Book Ratio0.77-0.61-0.56---
Return on Invested Capital-12.46-10.42-15.04---15.12
Quick Ratio9.8911.756.34--4.04
Current Ratio9.8911.756.34--4.04

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Net Income-88.41-82.96--105.21-68.24-
Depreciation5.065.11-6.316.47-
Other Funds (Non Cash)3.831.95-26.181.74-
Funds from Operations-79.52-75.89--72.72-60.04-
Extraordinary Item0.000.00-0.000.00-
Changes in Working Capital14.56-13.91-39.985.52-
Cash from Operating Activities-64.96-89.80--32.74-54.52-
Capital Expenditures-0.25-0.26--21.72-22.36-
Net Assets From Acquisitions0.000.00-0.000.00-
Sale of Fixed Assets and Businesses0.000.00-0.000.00-
Purchase or Sale of Investments46.68-202.96--14.16-191.50-
Purchase of Investments-79.82-306.95--68.91-252.50-
Sale Or Maturity of Investments126.50104.00-54.7561.00-
Other Uses0.000.00-0.000.00-
Other Sources0.000.00-0.000.00-
Cash from Investing Activities46.43-203.22--35.88-213.85-
Cash Dividends Paid0.000.00-0.000.00-
Preferred Dividends (Cash Flow)0.000.00----
Change in Capital Stock0.03349.31-0.52350.23-
Repurchase of Common Pref Stock0.000.00-0.000.00-
Sale of Common Pref Stock0.03349.31-0.52350.23-
Proceedsfrom Stock Options0.03349.31-0.52350.23-
Issuance or Reduction of Debt, Net0.000.00-0.000.00-
Change in Long Term Debt0.000.00-0.000.00-
Issuance of Long Term Debt0.000.00-0.000.00-
Reduction of Long Term Debt0.000.00-0.000.00-
Net Financing Active Other Cash Flow0.000.00-0.000.00-
Other Financing Activities Uses0.000.00-0.000.00-
Cash from Financing Activities0.03349.31-0.52350.23-
Net Change in Cash-18.5056.29--68.0981.86-
Free Cash Flow-65.21-90.06--54.45-76.88-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.93%5.5M25.3M556.62K
2026-10-1525.23%6.4M25.3M508.82K
2026-09-3024.93%6.3M25.3M485.47K
2026-09-1521.59%5.5M25.3M460.46K
2026-08-3120.86%5.3M25.3M401.44K
2026-08-1416.51%4.2M25.3M379.22K
2026-07-3119.23%4.9M25.4M365.80K
2026-07-1518.25%4.6M25.4M355.64K
2026-06-3018.27%4.6M25.4M352.32K
2026-06-1517.77%4.5M25.4M337.85K
2026-05-2916.04%4.1M25.4M354.59K
2026-05-1514.24%3.6M25.4M355.38K
2026-04-3012.53%3.4M27.0M442.45K
2026-04-1511.85%3.6M30.0M501.89K
2026-03-3111.05%3.3M30.0M535.02K
2026-03-137.23%2.2M30.0M559.84K
2026-02-275.32%1.6M30.0M699.87K
2026-02-132.90%0.9M30.0M1.08M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-268-KCurrent report2026-10-26SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-02SCHEDULE 13G/ASEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-148-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-038-KCurrent report2026-07-31SEC
2026-06-153Initial statement of beneficial ownership of securities2026-06-15SEC
2026-06-108-KCurrent report2026-06-05SEC
2026-06-018-KCurrent report2026-05-30SEC
2026-05-15SCHEDULE 13GSEC
2026-05-13SCHEDULE 13GSEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-05-06SCHEDULE 13GSEC
2026-04-29SCHEDULE 13GSEC
2026-03-308-KCurrent report2026-03-30SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-02-18SCHEDULE 13GSEC
2026-02-12SCHEDULE 13DSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-091.03M100
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0251.12M500
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC10.19%
BlackRock, Inc.7.91%
Foresite Capital Management IV, LLC3.59%
Merck & Co., Inc.3.08%
T. Rowe Price Investment Management, Inc.2.95%
Foresite Capital Management V, LLC2.44%
Capital World Investors2.17%
PRICE T ROWE ASSOCIATES INC /MD/1.86%
VANGUARD CAPITAL MANAGEMENT LLC1.70%
GEODE CAPITAL MANAGEMENT, LLC1.39%

Funds

Fund% owned
Fidelity Contrafund2.36%
Select Biotechnology Portfolio2.16%
SMALLCAP World Fund Inc2.11%
T. Rowe Price Small-Cap Value Fund, Inc.1.71%
Fidelity Growth Company Fund1.35%
BlackRock Health Sciences Opportunities Portfolio1.33%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.22%
iShares Russell 2000 ETF0.94%
T. Rowe Price Health Sciences Fund, Inc.0.64%
T. Rowe Price New Horizons Fund, Inc.0.61%

OakChart. EIKN. Cached 15 minutes.